非洛地平缓释片在中国高血压患者治疗中的应用

Application of felodipine sustained-release tablets in the hypertension treatment in China

BACKGROUND: Felodipine sustained-release tablets are taken orally once daily, which not only exhibit a flat plasma-concentration curve, but also have characteristics of stable effect-acting, good absorption in vivo, high bioavailability and good compliance. OBJECTIVE: To introduce the application status of felodipine sustained-release tablets in the hypertensive treatment of China. METHODS: A computer-based research of CNKI database was performed for literatures published from January 1, 2005 to July 1, 2016. Using the keywords of “felodipine sustained-release tablets, hepertension”, 174 articles were retrieved; and when retrieving “felodipine sustained-release tablets, materials”, 22 were obtained. Thirty literatures were enrolled finally for analysis according to the exclusion criteria. RESULTS AND CONCLUSION: Felodipine sustained-release tablets have been popularized to the hypertensive treatment in our country, and obtain satisfactory treatment outcomes for mild and moderate spontaneous hepertension, which are similar with those of the nifedipine sustained-release tablets, metoprolol sustained-release tablets and benazepril hydrochloride tablets. Felodipine sustained-release tablets also induce slight adverse reactions, such as headache, flush, palpation and swelling of ankles. For patients with hypertension cannot be alleviated through single use of felodipine sustained-release tablets, combination with other types of antihypertensive drugs including beta blockers, angiotensin converting enzyme inhibitors and diuretics is advisable. Compound felodipine sustained-release tablets have been used in clinic, and numerous multicenter, double-blind, randomized control trials have proved its effectiveness and safety. Therefore, compound felodipine sustained-release tablets are another choice when single treatment shows no improvement on patients with spontaneous hypertension.